Prof. Dr. Claus R. Bartram Director Institute of Human Genetics, Heidelberg Dean, Medical Faculty Heidelberg
Institute of Human Genetics Im Neuenheimer Feld 366 69120 Heidelberg 06221-565151 (phone) 06221-565155 (fax) cr_bartram@med.uni-heidelberg.de
SCIENTIFIC VITA
Graduation (Medicine) and M.D. degree (summa cum laude), University of Hamburg
1979 - 1982 Specialization in Pediatrics at the University Childrens’ Hospital in Düsseldorf 1982 - 1983 DFG Scholarship at the Erasmus University Rotterdam,
1984 - 1985 Specialization in Pediatrics at the University Childrens’ Hospital in Ulm
Board Certification in Pediatrics (1988)
Habilitation (Pediatrics) at the University of Ulm
Associate Professor and Head of the Section Molecular Biology, Department of
Appointed to the Chair of Clinical Molecular Biology at the University of Ulm Board Certification in Human Genetics (1995).
Appointed to the Chair of Human Genetics at the University of Heidelberg Director of the Institute of Human Genetics, University of Heidelberg (01.10.1995)
Appointmented to the Chair of Clinical Genetics at the Erasmus University in
Science Award from the Kind-Philipp-Foundation for Leukemia Research (1984); Science Award from the City of Ulm (1987); The Artur Pappenheim Award from the German Society for Hematology and Oncology (1989); Science Award from the Johann Georg Zimmermann Foundation for Cancer Research (1990); Mildred Scheel Memorial Lecture from the German Cancer Aid (1992); Robert Pfleger Award from the Dr. Robert Pfleger Foundation (1992); The Wilhelm Warner Foundation Science Award (1993); Merckle Award for Research from the University of Ulm (1994); Redlich Memorial Lectureship in Hematology, Visiting Professor at the Cedars-Sinai Medical Center, UCLA (1995); Lingen Foundation Science Award (1996); German Cancer Aid Award (2000)
FIELDS OF INTEREST
Cancer genetics, molecular characterization of hematopoietic neoplasias, minimal residual disease, hereditary cancer disposition.
SELECTED PUBLICATIONS
Wirtenberger M, Frank B, Hemminki K, Klaes R, Schmutzler RK, Wappenschmidt B, Meindl A, Kiechle M, Arnold N, Weber BH, Niederacher D, Bartram CR, Burwinkel B (2006). Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. Carcinogenesis 27, 1655- 1660 Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Welte K, Ludwig WD, Bartram CR, Zanger UM, Eichelbaum M, Schrappe M, Schwab M (2005). Thiopurine methyltransferase (TPMT) genotype is an independent modulator of early treatment response to 6-mercaptopurine in childhood acute lymphoblastic leukaemia. JAMA 293, 1485-1489 Cario G, Stanulla M, Fine BM, Teuffel O, v Neuhoff N, Schrauder A, Flohr T, Schafer BW, Bartram CR, Welte K, Schlegelberger B, Schrappe M (2005). Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 105, 821-826 Willemse MJ, Seriu T, d'Aniello E, Hop WCJ, Panzer-Grumayer ER, Biondi A, Schrappe M, Kamps WA, Masera G, Gadner H, Riehm H, Bartram CR, van Dongen JJM (2002). Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor-B-ALL. Blood 99, 4386-4393 Gleißner B, Gokbuget N, Bartram CR, Janssen LAJ, Rieder H, Janssen JWG, Fonatsch C, Heyll A, Voliotis D, Beck J, Lipp T, Munzert G, Maurer J, Hoelzer D, Thiel E (2002). Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99, 1536-1543 Tsukasaki K, Krebs J, Nagai K, Tomonaga M, Koeffler HP, Bartram CR, Jauch A (2001). Comparative genomic hybridization (CGH) analysis of adult T-cell leukemia/lymphoma (ATL): correlation with clinical course. Blood 97, 3875-3881 Janssen JWG, Vaandrager JW, Heuser T, Jauch A, Kluin PM, Geelen E, Bergsagel PL, Kuehl WM, Drexler HG, Otsuki T, Bartram CR, Schuuring E (2000). Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood 95, 2691-2698, 2000. Kamatsu N, Takeuchi S, Ikezoe T, Tasaka T, Hatta Y, Machida H, Williamson IK, Bartram CR, Koeffler HP, Taguchi H (2000). Mutations of the E2F4 gene in hematological malignancies having microsatellite instability. Blood 95, 1509-1510 Nakao M, Janssen JW, Flohr T, Bartram CR (2000). Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. Cancer Res 60, 3281-3289 Van Dongen JJM, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MAC, Cazzaniga G, Hettinger K, van der Does-van der Berg A, Hop WCJ, Riehm H, Bartram CR (1998). Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 352, 1731-1738
Organism list not requested in this search BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL% XANTHOHUMOL (FLAVONOID) PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 31.4 MICROMOLS/ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP1A2. PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30201 *PHARMACOLOGY OF COMPOUND - IN VITRO * C
Inhaltsverzeichnis Konsolidierung in vollem Gange – Seite 10-14Ausgewählte Merger- und Übernahmeszenarien Executive Summary Die Entwicklung zur „customized medicine“ schreitet mitder sprunghaften Verbesserung diagnostischer Testver-Der Life Sciences-Sektor wird weiterhin zu den innovations-fahren spürbar voran. Die Basis hierfür liefern die Ergebnissegetriebenen und wachstums